智通财经APP讯，派格生物医药-B(02565)发布截至2025年6月30日止6个月中期业绩，该集团取得其他净收入人民币17.8万元(单位下同)，研发开支2629.4万元，每股亏损0.25元。
截至本公告日期，我们在于美国及中国推进技术创新、产品管线及业务营运方面取得重大进展。
截至本公告日期，派格生物已成功构建覆盖6款针对慢性疾病领域的在研药物管线矩阵。公司核心战略聚焦于代谢性疾病及其并发症的治疗，通过持续创新，内部评估显示多款候选药物兼具“同类首创”(FIC)与“同类最优”(BIC)的双重价值潜力，为未来市场竞争力奠定坚实基础。
由于PB-119的NDA已获国家药监局受理，我们预期将于不久的将来在中国商业化PB-119。于上市后，我们预期会产生作为上市公司经营的相关成本。由于我们候选药物的开发状态、与合作伙伴的潜在合作时间表及条款、监管批准时间表及候选药物的商业化，我们预期我们的财务表现将于不同期间内波动。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.